Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating switching virologically suppressed HIV-1 patients from boosted protease inhibitor regimens to Bictegravir/Emtricitabine/Tenofovir Ala…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Bictegravir/Emtricitabine/Tenofovir Alafenamide (Bictegravir/emtricitabine/tenofovir alafenamide)
• Boosted atazanavir (Atazanavir boosted with ritonavir)
• Boosted darunavir (Darunavir boosted with ritonavir or cobicistat)
• Emtricitabine/Tenofovir (FTC/TDF) (Emtricitabine/Tenofovir disoproxil fumarate)
• abacavir/lamivudine (abacavir/lamivudine)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-06-06